Concord Coalition Releases Issue Brief on Administration's IMA...( ...),Health
Navigation Links
Concord Coalition Releases Issue Brief on Administration's IMAC Proposal
Date:7/31/2009
'/>"/>
| SOURCE The Concord Coalition Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Concord Coalition Warns That Health Care Reform Efforts Must Improve Nations Financial Outlook
2. Davis Vision, United Concordia Dental and The Pittsburgh Pirates Team Up to Provide Free Dental and Vision Screenings
3. United Concordia and Texas Oral Health Coalition Partner to Offer Free Dental Services
4. Concord Coalition Says New Trustees Report Demonstrates the Importance of Health Care Cost Control
5. United Concordia Provides $100,000 in Free Dental Services
6. Davis Vision, Visionworks, United Concordia Dental and Louisiana State University School of Dentistry Partner with Hands on New Orleans
7. United Concordia Dental Enhances Its Web-Based Find a Dentist Tool
8. National Dental Insurer United Concordia Successfully Launches Real-Time Claims Processing with Tesia-PCI
9. United Concordia Celebrates National Childrens Dental Health Month
10. Speed eClaim Helps National Dental Insurer United Concordia Process Claims Quickly, Efficiently and Electronically
11. VivoMetrics LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project
Post Your Comments:
Breaking Medicine News(10 mins):Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 2Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 4Health News:Social Networking Community Reaches Out to Persons With Illnesses and Disabilities 2Health News:Social Networking Community Reaches Out to Persons With Illnesses and Disabilities 3Health News:Social Networking Community Reaches Out to Persons With Illnesses and Disabilities 4Health News:Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche 2Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 2Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 3
[0] New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V)[0] Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma[0] Social Networking Community Reaches Out to Persons With Illnesses and Disabilities [0] Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche[0] New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director
Other Medicine News:Health News:Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer 2Health News:Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer 3Health News:Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer 4Health News:More States Move to Require Hospitals to Screen Patients for MRSA 2Health News:More States Move to Require Hospitals to Screen Patients for MRSA 3Health News:More States Move to Require Hospitals to Screen Patients for MRSA 4Health News:Global Cervical Artificial Disc Market to Hit $1 Billion by 2012 2Health News:Intercim Launches Pertinence Suite Powered by Velocity 2Health News:Intercim Launches Pertinence Suite Powered by Velocity 3Health News:Intercim Launches Pertinence Suite Powered by Velocity 4Health News:MedAptus Experiences Record Growth of 70 Percent 2Health News:MedAptus Experiences Record Growth of 70 Percent 3
Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast CancerMore States Move to Require Hospitals to Screen Patients for MRSACompetitive Intelligence: Information Collection TacticsGlobal Cervical Artificial Disc Market to Hit $1 Billion by 2012Intercim Launches Pertinence Suite Powered by VelocityMedAptus Experiences Record Growth of 70 Percent
Breaking Medicine Technology:Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Diabetes Drugs Go Head to Head in Study 62570 1Diabetes Drugs Go Head to Head in Study 62570 2Diabetes Drugs Go Head to Head in Study 62570 3Bullies May Intimidate Siblings Too 62568 1Bullies May Intimidate Siblings Too 62568 2Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment 62566 1Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment 62566 2
[0] Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website[0] Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition[0] Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
Other Medicine Technology:Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 2Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 3
Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease ControlVion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |